Timeline
2022
Softhale successfully completed its first surveillance audit for ISO 13485 –
March 20222021
invoX Pharma acquires Softhale N.V. –
March 2021
On 22 March 2021, invoX Pharma Ltd, a research-driven global biopharmaceutical company, entered into an agreement to fully acquire Softhale N.V.
2019
Successful series B fundraising –
February 2019
Softhale’s proprietary device technology is protected by more than 15 patents. Our portfolio also expanded with a branded high-end product.
2018
Internal team growth –
December 2018
Throughout 2018 and 2019, we recruited leading industry experts in the respiratory field with a long track record of bringing inhaled branded and generic products to market.
2017
Softhale’s first laboratory was opened –
August 2017Softhale moves into the office in Diepenbeek, Belgium –
April 20172016
Series A round completed –
December 2016
Successfully raised more than €1 million in Series A funding and a initiated a first customer-funded proof-of-concept study.
Softhale N.V. was established in Diepenbeek, Belgium –
February 20162015
Early-stage proof-of-concept work –
February 20152014
Business plan creation –
January 2014
After having conducted concept validation work and initial freedom-to-operate analysis, the team created the business plan that would help Softhale secure seed funding.
2013
First patent was filed by the group –
June 20132012
Starting conceptual work on a new generation Soft Mist Inhaler (SMI) –
January 2012
The founding members of Softhale started conceptual work on a new generation Soft Mist Inhaler (using proven expertise in microfluidic, medical device, pharmaceutical, and business development). Their collaboration resulted in the decision to start a pharmaceutical company.